Topic
Topic
UCHealth reports a 36-year-old mother of three, previously dying of melanoma, treated successfully with tumor-infiltrating lymphocyte (TIL) therapy — her own immune cells, expanded and reinfused.
OncLive reports low rates of post-discharge severe TRAEs and hospital readmissions after lifileucel in advanced melanoma. Cohort…
Dr. Ankit Mangla asks whether chemotherapy can bridge relapsed-refractory melanoma patients to TIL therapy, spotlighting the lymp…
Engineered NK cells spotted a cancer antigen the immune system usually misses and slowed melanoma in mice, a Bioengineer.org repo…
Obsidian Therapeutics will present updated Phase 1/2 data on amsoki-cel (OBX-115) in advanced melanoma at the SITC 2026 Annual Me…
Iovance Biotherapeutics shares surged after Barron's reported strong demand for its melanoma drug is driving company growth, sign…
